Myelodysplastic Syndrome (MDS)/ CMML

- Intermediate and High Risk
  - Untreated MDS
  - Relapsed/Refractory

- Myelodysplastic Syndrome (MDS)
  - IDH1
  - For transplant

- Chronic Myelomonocytic Leukemia (CMML)

- IDH1

- IRB#15953 Phase 2 treatment with SY-1425, a selective Retinoic Acid Receptor Alpha Agonist

- IRB#15977 Non Treatment National MDS Study (ECOG/ACRIN)

- IRB#15993 Study coming soon (relapsed/refractory MDS)

- IRB#16142 Ph1 Oral AG-120 treatment

- IRB#16867 Study coming soon (treatment naive high risk MDS)

- IRB#15619 Phase 1/2 Vadastuximab Talirine (SGN-CD33A) plus Standard of care chemo in intermediate to high risk MDS

- IRB#16142 Ph1 Oral AG-120 treatment with LOR-253